Comparison of the Effectiveness of the Ultrasound Guided Injections in Patients With Shoulder Impingement Syndrome
2021年8月19日 更新者：Dr. Burcu Metin Ökmen、Bursa Yüksek İhtisas Education and Research Hospital
Comparison of the Effectiveness of the Ultrasound Guided Subacromial, Acromioclavicular With Subacromial Injection and Suprascapular Nerve Block in Patients With Shoulder Impingement Syndrome ; A Randomized Controlled, Single Blind, Clinical Trial
Shoulder pain, which is the third most common cause of musculoskeletal pain, has different etiologies.
Muscle, bone structures and connective tissue pathologies can cause shoulder pain.
Impingement syndrome (IS), which can cover many terms such as rotator cuff disorders, tendinitis and tears, is one of the most common pathologies of shoulder pain.
研究概览
地位
完全的
详细说明
The hypothesis of this study was that injection types including ACJ would increase treatment efficacy.Therefore, this study investigated the six-month follow-up results of patients undergoing SA injection and SSNB and those receiving SA and ACJ injection.
研究类型
介入性
注册 (实际的)
88
阶段
- 第四阶段
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 65年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- patients aged 18-65,
- who were suffering from shoulder pain for more than three months and
- who were diagnosed with IS.
- All patients included in the study were diagnosed with IS using Shoulder Magnetic Resonance imaging.
Exclusion Criteria:
- the presence of cervical radiculopathy;
- undergoing shoulder operation before;
- the presence of central nervous system or
- the presence of rheumatological disease, and polyneuropathy;
- receiving physical therapy in the shoulder area with a diagnosis of IS within the last six months; and
- receiving any injection therapy in the past.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：subacromial injection
ultrasound (US)-guided subacromial injection
|
5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection.
In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
其他名称：
|
|
有源比较器：acromioclavicular joint and subacromial injection
ultrasound (US)-guided acromioclavicular joint and subacromial injection
|
5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection.
In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
其他名称：
|
|
有源比较器：suprascapular nerve block
ultrasound (US)-guided suprascapular nerve block
|
5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection.
In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Visual Analogue Scale (VAS)
大体时间：six month
|
for pain.
0: no pain at all, 10: worst pain imaginable
|
six month
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Shoulder pain and disability index (SPADI)
大体时间：six month
|
This scale was developed to measure pain and disability associated with shoulder pain.
It consists of two parts evaluating pain and disability.
|
six month
|
|
Short-Form 12 (SF-12)
大体时间：six month
|
The SF-12 has a physical (SF12-PCS) and mental (SF12-MCS) state assessment scale
|
six month
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Burcu Metin Ökmen, Assoc. Prof、University of Health Sciences, Yuksek Ihtisas Training and Research Hospital
- 学习椅：Korgün M Ökmen, Assoc. Prof、University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2017年1月1日
初级完成 (实际的)
2021年1月1日
研究完成 (实际的)
2021年1月1日
研究注册日期
首次提交
2021年8月18日
首先提交符合 QC 标准的
2021年8月19日
首次发布 (实际的)
2021年8月20日
研究记录更新
最后更新发布 (实际的)
2021年8月20日
上次提交的符合 QC 标准的更新
2021年8月19日
最后验证
2021年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.